NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 383 filers reported holding NEKTAR THERAPEUTICS in Q2 2018. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $796,000 | -49.7% | 39,828 | -41.7% | 0.07% | -58.6% |
| Q2 2020 | $1,582,000 | +671.7% | 68,345 | +493.1% | 0.16% | +636.4% |
| Q1 2020 | $205,000 | -78.8% | 11,524 | -60.0% | 0.02% | -60.7% |
| Q1 2019 | $967,000 | -9.1% | 28,800 | -11.1% | 0.06% | +1.8% |
| Q4 2018 | $1,064,000 | -7.6% | 32,400 | +71.4% | 0.06% | +37.5% |
| Q3 2018 | $1,152,000 | -88.8% | 18,900 | -91.1% | 0.04% | -81.2% |
| Q2 2018 | $10,312,000 | +768.7% | 211,200 | +205.6% | 0.21% | +446.2% |
| Q3 2016 | $1,187,000 | +42.8% | 69,100 | +18.3% | 0.04% | 0.0% |
| Q2 2016 | $831,000 | +193.6% | 58,400 | +247.6% | 0.04% | +129.4% |
| Q4 2015 | $283,000 | -39.7% | 16,800 | -60.7% | 0.02% | -51.4% |
| Q3 2015 | $469,000 | -6.2% | 42,800 | +7.0% | 0.04% | -53.3% |
| Q2 2015 | $500,000 | +228.9% | 40,000 | +236.1% | 0.08% | +177.8% |
| Q2 2014 | $152,000 | +46.2% | 11,900 | +19.0% | 0.03% | +200.0% |
| Q3 2013 | $104,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |